Combined Use of Savi Scout and Magtrace for Non-Palpable Breast Cancer: A Retrospective Study.
- 1London North West University Healthcare NHS Trust, London HA1 3UJ, UK.
- 2King's College Hospital NHS Foundation Trust, London BR6 8ND, UK.
- 3HCA Healthcare London Bridge Hospital, London SE1 2PR, UK.
Abstract
Background
Non-palpable breast cancer management has become less invasive and more efficient, driven by advances in tumor localization and sentinel lymph node (SLN) identification. Savi Scout, using a radar-based localization system, can be implanted into the tumor before neoadjuvant systemic therapy (NST). Magtrace, a superparamagnetic iron oxide nanoparticle for SLN detection, can be administered preoperatively. This study evaluated combining Savi Scout and Magtrace for breast-conserving surgery and SLN biopsy in non-palpable breast cancer.Methods
Patients who underwent breast-conserving surgery and SLN biopsy for non-palpable breast cancer using Savi Scout and Magtrace between December 2022 and June 2026 at HCA Healthcare London Bridge Hospital were retrospectively identified. Outcomes included successful tumor localization, SLN identification, intraoperative signal detection failure, margin status, re-excision rate and staining.Results
72 patients were identified (mean age 52 years, standard deviation ± 10), with a total of 78 breast lesions and 73 SLN biopsies. A total of 27.8% (20/72) underwent neo-adjuvant therapy with Savi Scout in situ. SLNs were identified using Magtrace in 95.9% (70/73) of SLN biopsies, with a mean of 2.7 (standard deviation ± 0.7) SLNs identified per procedure. A total of 78 Savi Scout devices were implanted, one for each lesion. Of these, 97.4% (76/78) were localizable intraoperatively, 100.0% (78/78) were retrieved and none migrated. One patient required re-excision for margin involvement.Conclusions
Combined use of Savi Scout and Magtrace is feasible, demonstrates high technical success, and offers pre-operative imaging flexibility in primary surgery for non-palpable breast cancers and post-NST patients. This study evaluates the combination of Savi Scout and Magtrace and demonstrates a practical approach for simultaneous tumor localization and SLN identification.
Related
- Core needle biopsy washout biomarkers combined with ultrasound for preoperative axillary risk stratification in breast cancer: a retrospective nomogram study with temporal validation
- Cytological Grading of Palpable Breast Lesions: Comparative Analysis of Masood, Modified Masood, and Yokohama system with Cytohistological Correlation at a Newly Established Tertiary Care Center in South India.
- Combined Pectoral Nerve Block and Intravenous Dexmedetomidine in Contemporary Multimodal Breast Cancer Analgesia: A Real-World Cohort Study
- Efficacy and safety of osimertinib combined with anlotinib in EGFR-mutant non-squamous non-small cell lung cancer with gradual progression after first-line osimertinib therapy: a single-center retrospective cohort study
- Fluoroscopic Catheter-Tip Positioning During Internal Jugular TIVAD Placement in Breast Cancer: A Two-Center Retrospective Cohort Study
BibTeX
@article{lloyddavies2026combined,
title = {{Combined Use of Savi Scout and Magtrace for Non-Palpable Breast Cancer: A Retrospective Study.}},
author = {Claire Lloyd-Davies and Abdul Kasem},
journal = {Cancers},
year = {2026},
month = oct,
doi = {10.3390/cancers18193197},
url = {https://europepmc.org/article/MED/42882892},
note = {CC BY},
}
RIS
TY - JOUR
TI - Combined Use of Savi Scout and Magtrace for Non-Palpable Breast Cancer: A Retrospective Study.
AU - Claire Lloyd-Davies
AU - Abdul Kasem
PY - 2026
DA - 2026/10/03
JO - Cancers
DO - 10.3390/cancers18193197
UR - https://europepmc.org/article/MED/42882892
AB - Background Non-palpable breast cancer management has become less invasive and more efficient, driven by advances in tumor localization and sentinel lymph node (SLN) identification. Savi Scout, using a radar-based localization system, can be implanted into the tumor before neoadjuvant systemic therapy (NST). Magtrace, a superparamagnetic iron oxide nanoparticle for SLN detection, can be administered preoperatively. This study evaluated combining Savi Scout and Magtrace for breast-conserving surgery and SLN biopsy in non-palpable breast cancer.Methods Patients who underwent breast-conserving surgery and SLN biopsy for non-palpable breast cancer using Savi Scout and Magtrace between December 2022 and June 2026 at HCA Healthcare London Bridge Hospital were retrospectively identified. Outcomes included successful tumor localization, SLN identification, intraoperative signal detection failure, margin status, re-excision rate and staining.Results 72 patients were identified (mean age 52 years, standard deviation ± 10), with a total of 78 breast lesions and 73 SLN biopsies. A total of 27.8% (20/72) underwent neo-adjuvant therapy with Savi Scout in situ. SLNs were identified using Magtrace in 95.9% (70/73) of SLN biopsies, with a mean of 2.7 (standard deviation ± 0.7) SLNs identified per procedure. A total of 78 Savi Scout devices were implanted, one for each lesion. Of these, 97.4% (76/78) were localizable intraoperatively, 100.0% (78/78) were retrieved and none migrated. One patient required re-excision for margin involvement.Conclusions Combined use of Savi Scout and Magtrace is feasible, demonstrates high technical success, and offers pre-operative imaging flexibility in primary surgery for non-palpable breast cancers and post-NST patients. This study evaluates the combination of Savi Scout and Magtrace and demonstrates a practical approach for simultaneous tumor localization and SLN identification.
SN - 2072-6694
ER -